一、基本信息
姓名：郝杨
职称：助理研究员
所在部门：bevictor伟德
研究方向：人类疾病模型及机制研究
办公电话：13252602124
电子邮件：yhao@jlu.edu.cn
二、学习与工作经历
2011.09 - 2015.06 BETVLCTOR伟德官方网站 实验动物专业 理学学士学位
2015.09 - 2018.06 BETVLCTOR伟德官方网站 动物学专业 理学硕士学位
2018.12 - 2023.01 莱顿大学 基础医学专业 博士学位
2023.03 - 2024.01 bevictor伟德 国际交流计划引进项目 博士后
2024.01 - 至今 bevictor伟德 国家海外博士后引才专项第一层次 博士后
三、主要科研工作
主要研究领域为癌症治疗和肿瘤免疫学机制的研究。研究方向主要包括以小鼠和人类为研究对象，基于多种小鼠肿瘤模型进行抗癌效率和免疫学机制的深入研究以及药物对乳腺炎等慢性疾病的发生发展机制研究。
熟悉癌症相关细胞信号通路的作用机制和研究手段、精通细胞培养和动物模型以及抗肿瘤药物作用机制研究，以及SCI的撰写。具有欧洲感染、免疫和耐受课程培训证书；欧洲Article9特定物种实验动物（鱼类）研究员证书，以及欧洲Article9基础实验动物研究员证书。
参与多项国家自然科学基金项目，并参加Oncode学术会议， NWO Chain化学会议，世界TGF-beta研讨会等多个国际学术会议。
四、科研成果
1. Ma S, Huis In't Veld RV, Hao Y, et al. Tumor Pigmentation Does Not Affect Light-Activated Belzupacap Sarotalocan Treatment but Influences Macrophage Polarization in a Murine Melanoma Model. Invest Ophthalmol Vis Sci. 2024;65(1):42.
2. Hao Y, Ji Z, Zhou H, et al. Lipid-based nanoparticles as drug delivery systems for cancer immunotherapy. MedComm (2020). 2023;4(4):e339.
3. Hao, Y, Ma S, Gu, Z, et al., Combination of photodynamic therapy and stimulator of interferon genes (STING) agonist inhibits colorectal tumor growth and recurrence. Cancer Commun (Lond). 2023;43(4):513-518.
4. Gu Z, Hao Y, Schomann T, et al. Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation. J Control Release. 2023;357:531-544.
5. Gu Z, Da Silva CG, Hao Y, et al. Effective combination of liposome-targeted chemotherapy and PD-L1 blockade of murine colon cancer. J Control Release. 2023;353:490-506.
6. Hao, Y, Chung CK, Gu, Z, et al. Combinatorial therapeutic approaches of photodynamic therapy and immune checkpoint blockade for colon cancer treatment. Mol Biomed. 2022;3(1):26
7. Yu Z, He Y, Schomann T, Wu K, Hao Y, et al., Rare-Earth-Metal (Nd3+, Ce3+ and Gd3+)-Doped CaF2: Nanoparticles for Multimodal Imaging in Biomedical Applications. Pharmaceutics. 2022; 14(12):2796.
8. Yu Z, He Y, Schomann T, Wu K, Hao Y, et al. Achieving Effective Multimodal Imaging with Rare-Earth Ion-Doped CaF2 Nanoparticles. Pharmaceutics. 2022;14(4):840.
9. Hao, Y, Gu, Z, Yu, Z, et al., Photodynamic Therapy in Combination with the Hepatitis B Core virus-like particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment. Cancers 2022;14(11):2724.
10. Cai M, Zeng Y, Liu M, You L, Huang H, Hao Y, et al. Construction of a Multifunctional Nano-Scale Metal-Organic Framework-Based Drug Delivery System for Targeted Cancer Therapy. Pharmaceutics. 2021 Nov 17;13(11):1945.
11. Dong X, Zeng Y, Zhang Z, Fu J, You L, He Y, Hao Y, et al. Hypericin-mediated photodynamic therapy for the treatment of cancer: a review. J Pharm Pharmacol. 2021 Mar 8;73(4):425-436.
12. Hao J, Li C, Lin C, Hao, Y., et al. Targeted point mutations of the m6A modification in miR675 using RNA-guided base editing induce cell apoptosis. Biosci Rep. 2020;40(5): BSR20192933.
13. Hao, Y., Baker, D., & Ten Dijke, P. (2019). TGF-beta-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci, 20(11).
14. Zhong X*, Liu D*, Hao Y*, et al. The expression of TET3 regulated cell proliferation in HepG2 cells. Gene. 2019; 698:113-119.
15. Shen Z, Ma Y, Ji Z., Hao, Y., et al. Arachidonic acid induces macrophage cell cycle arrest through the JNK signaling pathway. Lipids Health Dis. 2018;17(1):26.
16. Hao Y, Wang G, Lin C, et al. Valproic Acid Induces Decreased Expression of H19 Promoting Cell Apoptosis in A549 Cells. DNA Cell Biol. 2017;36(6):428-435.
17. Wang D*, Wang G*, Yang H*, et al. DNA methylation modulates H19 and IGF2 expression in porcine female eye. Genet Mol Biol. 2017;40(1):153-159.
18. Wang, D., Liu, Z., Yao, H., Hao, Y., et al. Disruption of NNAT, NAP1L5 and MKRN3 DNA methylation and transcription in rabbit parthenogenetic fetuses. Gene. 2017; 626: 158-162.
19. Ji ZH, Ren WZ, Gao W, Hao, Y., et al. Analyzing the innate immunity of NIH hairless mice and the impact of gut microbial polymorphisms on Listeria monocytogenes infection. Oncotarget. 2017;8(63):106222-106232
